BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance; · Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating

  • Nicholas Brown
Period2 Apr 2019

Media coverage

1

Media coverage

  • TitleBerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance; · Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating
    Media name/outletPR Newswire
    Country/TerritoryUnited States
    Date2/04/19
    PersonsNicholas Brown
View all 1
View less